3 US Generics and Branded Medicines Company, Global Generics Maker and Chronic Therapy Brands Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences

US generics and chronic brand pharma stocks offer a focused view of a sector where demand keeps widening. Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences cover a US generics and branded medicines company, a global generics maker and a chronic therapy brands company.

This list covers three US generics and chronic brand pharma stocks with complete current figures: Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are US Generics and Chronic Brand Pharma Stocks?

US generics and chronic brand pharma stocks are listed drug makers that sell generics in regulated markets and chronic care brands in India across heart, diabetes and stomach care. Their earnings depend on launches, approvals, plant quality and prescriptions.

US Generics and Chronic Brand Pharma Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing US generics and chronic brand pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do US Generics and Chronic Brand Pharma Stocks Have a Strong Roadmap in India?

US generics and chronic brand pharma stocks have a strong roadmap in India because a wide product pipeline, trusted brands and rising healthcare access keep widening the revenue base.

• Product pipeline. New launches in regulated markets add revenue.
• Chronic care. Cardiac and diabetes brands retain prescribers.
• Global reach. Plants serve markets across continents.

Why Alembic Pharmaceuticals Features Among These US Generics and Chronic Brand Pharma Stocks

Among the US generics and chronic brand pharma stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why Dr. Reddy's Laboratories Features Among These US Generics and Chronic Brand Pharma Stocks

Among the Vadodara generics and global generics shares on this list, Dr. Reddy's Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.

Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.

The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.

Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.

Why Eris Lifesciences Features Among These US Generics and Chronic Brand Pharma Stocks

Among the three companies on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Alembic Pharmaceuticals vs Dr. Reddy's Laboratories vs Eris Lifesciences on Key Financials

The table below sets the three US generics and chronic brand pharma stocks side by side on revenue, profit and margin, using reported figures.

Eris Lifesciences posts the highest return on equity in this group at 15.9%. Dr. Reddy's Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with US generics and chronic brand pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in US Generics and Chronic Brand Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these US generics and chronic brand pharma stocks, the main points are: Long-term Vadodara generics and global generics shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices abroad can fall.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter US generics and chronic brand pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on US Generics and Chronic Brand Pharma Stocks

US generics and chronic brand pharma stocks reward patient research into demand, execution and financial strength. Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences each have a clear plan to grow. Based on the 26 October 2026 close, Alembic Pharmaceuticals trades at Rs 766.4, Dr. Reddy's Laboratories at Rs 1,310.9 and Eris Lifesciences at Rs 1,105.2.

Download the Univest iOS App or Univest Android App to track US generics and chronic brand pharma stocks, set price alerts and get research-backed stock ideas.

What are US generics and chronic brand pharma stocks?

Ans. US generics and chronic brand pharma stocks are listed drug makers that sell generics in regulated markets and chronic care brands in India across heart, diabetes and stomach care. Their earnings depend on launches, approvals, plant quality and prescriptions. This list looks at three of them, Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which US generics and chronic brand pharma stocks are covered in this list?

Ans. This list covers Alembic Pharmaceuticals, Dr. Reddy's Laboratories and Eris Lifesciences. Based on the 26 October 2026 close, Alembic Pharmaceuticals traded at Rs 766.4, Dr. Reddy's Laboratories at Rs 1,310.9 and Eris Lifesciences at Rs 1,105.2. Their return on equity ranges from 11.1% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 22.9%.

Why do US generics and chronic brand pharma stocks have a strong future roadmap in India?

Ans. US generics and chronic brand pharma stocks have a strong roadmap in India because a wide product pipeline, trusted brands and rising healthcare access keep widening the revenue base. The main drivers are as follows. Product pipeline. New launches in regulated markets add revenue. Chronic care. Cardiac and diabetes brands retain prescribers. Global reach. Plants serve markets across continents. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has Dr. Reddy's Laboratories performed financially?

Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What risks should investors check before buying US generics and chronic brand pharma stocks?

Ans. Investors should check a few risks before buying US generics and chronic brand pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of US generics and chronic brand pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.